Cargando…

Premedications for Cancer Therapies: A Primer for the Hematology/Oncology Provider

Chemotherapeutic agents and radiation therapy are associated with numerous potential adverse events (AEs). Many of these common AEs, namely chemotherapy- or radiation-induced nausea and vomiting, hypersensitivity reactions, and edema, can lead to deleterious outcomes (such as treatment nonadherence...

Descripción completa

Detalles Bibliográficos
Autores principales: Clemmons, Amber, Gandhi, Arpita, Clarke, Andrea, Jimenez, Sarah, Le, Thuy, Ajebo, Germame
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8631343/
https://www.ncbi.nlm.nih.gov/pubmed/35295545
http://dx.doi.org/10.6004/jadpro.2021.12.8.4
_version_ 1784607539969654784
author Clemmons, Amber
Gandhi, Arpita
Clarke, Andrea
Jimenez, Sarah
Le, Thuy
Ajebo, Germame
author_facet Clemmons, Amber
Gandhi, Arpita
Clarke, Andrea
Jimenez, Sarah
Le, Thuy
Ajebo, Germame
author_sort Clemmons, Amber
collection PubMed
description Chemotherapeutic agents and radiation therapy are associated with numerous potential adverse events (AEs). Many of these common AEs, namely chemotherapy- or radiation-induced nausea and vomiting, hypersensitivity reactions, and edema, can lead to deleterious outcomes (such as treatment nonadherence or cessation, or poor clinical outcomes) if not prevented appropriately. The occurrence and severity of these AEs can be prevented with the correct prescribing of prophylactic medications, often called “premedications.” The advanced practitioner in hematology/oncology should have a good understanding of which chemotherapeutic agents are known to place patients at risk for these adverse events as well as be able to determine appropriate prophylactic medications to employ in the prevention of these adverse events. While several guidelines and literature exist regarding best practices for prophylaxis strategies, differences among guidelines and quality of data should be explored in order to accurately implement patient-specific recommendations. Herein, we review the existing literature for prophylaxis and summarize best practices
format Online
Article
Text
id pubmed-8631343
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Harborside Press LLC
record_format MEDLINE/PubMed
spelling pubmed-86313432022-03-15 Premedications for Cancer Therapies: A Primer for the Hematology/Oncology Provider Clemmons, Amber Gandhi, Arpita Clarke, Andrea Jimenez, Sarah Le, Thuy Ajebo, Germame J Adv Pract Oncol Review Chemotherapeutic agents and radiation therapy are associated with numerous potential adverse events (AEs). Many of these common AEs, namely chemotherapy- or radiation-induced nausea and vomiting, hypersensitivity reactions, and edema, can lead to deleterious outcomes (such as treatment nonadherence or cessation, or poor clinical outcomes) if not prevented appropriately. The occurrence and severity of these AEs can be prevented with the correct prescribing of prophylactic medications, often called “premedications.” The advanced practitioner in hematology/oncology should have a good understanding of which chemotherapeutic agents are known to place patients at risk for these adverse events as well as be able to determine appropriate prophylactic medications to employ in the prevention of these adverse events. While several guidelines and literature exist regarding best practices for prophylaxis strategies, differences among guidelines and quality of data should be explored in order to accurately implement patient-specific recommendations. Herein, we review the existing literature for prophylaxis and summarize best practices Harborside Press LLC 2021-11 2021-11-01 /pmc/articles/PMC8631343/ /pubmed/35295545 http://dx.doi.org/10.6004/jadpro.2021.12.8.4 Text en © 2021 Harborside™ https://creativecommons.org/licenses/by-nc-nd/3.0/This article is distributed under the terms of the Creative Commons Attribution Non-Commercial Non-Derivative License, which permits unrestricted non-commercial and non-derivative use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Clemmons, Amber
Gandhi, Arpita
Clarke, Andrea
Jimenez, Sarah
Le, Thuy
Ajebo, Germame
Premedications for Cancer Therapies: A Primer for the Hematology/Oncology Provider
title Premedications for Cancer Therapies: A Primer for the Hematology/Oncology Provider
title_full Premedications for Cancer Therapies: A Primer for the Hematology/Oncology Provider
title_fullStr Premedications for Cancer Therapies: A Primer for the Hematology/Oncology Provider
title_full_unstemmed Premedications for Cancer Therapies: A Primer for the Hematology/Oncology Provider
title_short Premedications for Cancer Therapies: A Primer for the Hematology/Oncology Provider
title_sort premedications for cancer therapies: a primer for the hematology/oncology provider
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8631343/
https://www.ncbi.nlm.nih.gov/pubmed/35295545
http://dx.doi.org/10.6004/jadpro.2021.12.8.4
work_keys_str_mv AT clemmonsamber premedicationsforcancertherapiesaprimerforthehematologyoncologyprovider
AT gandhiarpita premedicationsforcancertherapiesaprimerforthehematologyoncologyprovider
AT clarkeandrea premedicationsforcancertherapiesaprimerforthehematologyoncologyprovider
AT jimenezsarah premedicationsforcancertherapiesaprimerforthehematologyoncologyprovider
AT lethuy premedicationsforcancertherapiesaprimerforthehematologyoncologyprovider
AT ajebogermame premedicationsforcancertherapiesaprimerforthehematologyoncologyprovider